Circulating Aldosterone and Natriuretic Peptides in the General Community: Relationship to Cardiorenal and Metabolic Disease
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
We sought to investigate the role of aldosterone as a mediator of disease and its relationship with the counter-regulatory natriuretic peptide (NP) system. We measured plasma aldosterone (n=1674; aged≥45 years old) in a random sample of the general population from Olmsted County, MN. In a multivariate logistic regression model, aldosterone analyzed as a continuous variable was associated with hypertension (odds ratio [OR]=1.75; 95% confidence interval [CI]=1.57–1.96; P <0.0001), obesity (OR=1.34; 95% CI=1.21–1.48; P <0.0001), chronic kidney disease (OR=1.39; 95% CI=1.22–1.60; P <0.0001), central obesity (OR=1.47; 95% CI=1.32–1.63; P <0.0001), metabolic syndrome (OR=1.41; 95% CI=1.26–1.58; P <0.0001), high triglycerides (OR=1.23; 95% CI=1.11–1.36; P <0.0001), concentric left ventricular hypertrophy (OR=1.22; 95% CI=1.09–1.38; P =0.0007), and atrial fibrillation (OR=1.24; 95% CI=1.01–1.53; P =0.04), after adjusting for age and sex. The associations with hypertension, central obesity, metabolic syndrome, triglycerides, and concentric left ventricular hypertrophy remained significant after further adjustment for body mass index, NPs, and renal function. Furthermore, aldosterone in the highest tertile correlated with lower NP levels and increased mortality. Importantly, most of these associations remained significant even after excluding subjects with aldosterone levels above the normal range. In conclusion, we report that aldosterone is associated with hypertension, chronic kidney disease, obesity, metabolic syndrome, concentric left ventricular hypertrophy, and lower NPs in the general community. Our data suggest that aldosterone, even within the normal range, may be a biomarker of cardiorenal and metabolic disease. Further studies are warranted to evaluate a therapeutic and preventive strategy to delay the onset and progression of disease, using mineralocorticoid antagonists or chronic NP administration in high-risk subjects identified by plasma aldosterone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bordicchia, M., Liu, D., Amri, E.-Z., Ailhaud, G., Dessì-Fulgheri, P., Zhang, C., Takahashi, N., Sarzani, R., & Collins, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59701 · Cited by 872 · cited 1×
“Indeed, a cotherapeutic strategy to compensate the imbalance between these 2 counter-regulatory systems is worthy of further investigation.(40,41) The current study has several strengths.”
BackgroundSelf-citationBriones, A. M., Nguyen Dinh Cat, A., Callera, G. E., Yogi, A., Burger, D., He, Y., Corrêa, J. W., Gagnon, A. M., Gomez-Sanchez, C. E., Gomez-Sanchez, E. P., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.190223 · Cited by 375
Sowers, J. R., Whaley-Connell, A., & Epstein, M. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-11-200906020-00005 · Cited by 351
Acute and chronic regulation of aldosterone production
Hattangady, N. G., Olala, L. O., Bollag, W. B., & Rainey, W. E. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.07.034 · Cited by 347
Plasma aldosterone is independently associated with the metabolic syndrome
Bochud, M., Nussberger, J., Bovet, P., Maillard, M. R., Elston, R. C., Paccaud, F., Shamlaye, C., & Burnier, M. (2006) · Hypertension · doi:10.1161/01.hyp.0000231338.41548.fc · Cited by 226
Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets
Luther, J. M., Luo, P., Kreger, M. T., Brissova, M., Dai, C., Whitfield, T. T., Kim, H. S., Wasserman, D. H., Powers, A. C., & Brown, N. J. (2011) · Diabetologia · doi:10.1007/s00125-011-2158-9 · Cited by 109
Cited by
Muñoz-Durango, N., Fuentes, C., Castillo, A., González-Gómez, L., Vecchiola, A., Fardella, C., & Kalergis, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17070797 · Cited by 282
Kolkhof, P., Jaisser, F., Kim, S.-Y., Filippatos, G., Nowack, C., & Pitt, B. (2016) · Handbook of Experimental Pharmacology · doi:10.1007/164_2016_76 · Cited by 180
Atrial Fibrillation and Hypertension
Dzeshka, M. S., Shantsila, A., Shantsila, E., & Lip, G. Y. H. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.08934 · Cited by 148
Hypertension in Obesity and the Impact of Weight Loss
Cohen, J. B. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0912-4 · Cited by 147
“The etiology of resistant hypertension in these patients is likely multifactorial, including dysfunctional neurohormonal pathways, particularly increased aldosterone secretion, as well as the systemic effects of adipokines such as leptin and adiponectin [27, 28].”
InfluentialChaudhuri, A., Ghanim, H., & Arora, P. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14601 · Cited by 120
Metadata
- Authors
- Buglioni, A., Cannone, V., Cataliotti, A., Sangaralingham, S. J., Heublein, D. M., Scott, C. G., Bailey, K. R., Rodeheffer, R. J., Dessì-Fulgheri, P., Sarzani, R., & Burnett, J. C.
- Venue
- Hypertension
- Published
- 2015-01
- Volume
- 65
- Issue
- 1
- Pages
- 45-53
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2118113989
- Cited by
- 85
- References
- 6
- FWCI
- 8.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Circulating Aldosterone and Natriuretic Peptides in the General Community: Relationship to Cardiorenal and Metabolic Disease. https://app.cochat.ai/papers/10.1161/hypertensionaha.114.03936
- The paper
- Buglioni, A., Cannone, V., Cataliotti, A., Sangaralingham, S. J., Heublein, D. M., Scott, C. G., Bailey, K. R., Rodeheffer, R. J., Dessì-Fulgheri, P., Sarzani, R., & Burnett, J. C. (2015). Circulating Aldosterone and Natriuretic Peptides in the General Community: Relationship to Cardiorenal and Metabolic Disease. Hypertension. https://doi.org/10.1161/hypertensionaha.114.03936
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.